Rigel Pharmaceuticals (FRA:RI2) PE Ratio (TTM): 2.11 (As of Jul. 03, 2026) — 71% Below Median


FRA:RI2 Rigel Pharmaceuticals Inc FRA:RI2
76 GF Score
Price €33.80
GF Value €24.48
! 7 Warning Signs
View Full Analysis

What is Rigel Pharmaceuticals PE Ratio (TTM)?

Rigel Pharmaceuticals FRA:RI2 +1.08% 76 PE Ratio (TTM) is 2.11 as of Jul. 03, 2026, which is 71% below its 10-year median of 7.16. GuruFocus rates FRA:RI2 with a GF Score™ of 76/100 and a GF Value™ of €24.48. The stock has 7 warning signs investors should review. Among 272 Biotechnology companies, Rigel Pharmaceuticals ranks better than 93.38% on this metric.

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-03), Rigel Pharmaceuticals's share price is €33.80. Rigel Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €16.03. Therefore, Rigel Pharmaceuticals's PE Ratio (TTM) for today is 2.11.


The historical rank and industry rank for Rigel Pharmaceuticals's PE Ratio (TTM) or its related term are showing as below:

FRA:RI2' s PE Ratio (TTM) Range Over the Past 10 Years
Min: 1.36   Med: 7.16   Max: 125.5
Current: 2.07


During the past 13 years, the highest PE Ratio (TTM) of Rigel Pharmaceuticals was 125.50. The lowest was 1.36. And the median was 7.16.


FRA:RI2's PE Ratio (TTM) is ranked better than
93.38% of 272 companies
in the Biotechnology industry
Industry Median: 27.48 vs FRA:RI2: 2.07

Rigel Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Mar. 2026 was €0.38. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €16.03.

As of today (2026-07-03), Rigel Pharmaceuticals's share price is €33.80. Rigel Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was €16.03. Therefore, Rigel Pharmaceuticals's PE Ratio without NRI for today is 2.11.

During the past 13 years, Rigel Pharmaceuticals's highest PE Ratio without NRI was 125.50. The lowest was 1.36. And the median was 7.16.

Rigel Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2026 was €0.38. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was €16.03.

During the past 12 months, Rigel Pharmaceuticals's average EPS without NRI Growth Rate was 804.30% per year.

During the past 13 years, Rigel Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 68.60% per year. The lowest was -21.40% per year. And the median was 17.15% per year.

Rigel Pharmaceuticals's EPS (Basic) for the three months ended in Mar. 2026 was €0.41. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €17.19.


Rigel Pharmaceuticals  (FRA:RI2) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Rigel Pharmaceuticals PE Ratio (TTM) Related Terms


Rigel Pharmaceuticals PE Ratio (TTM) Historical Data

* Premium members only.

The historical data trend for Rigel Pharmaceuticals's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rigel Pharmaceuticals PE Ratio (TTM) Chart

Rigel Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss At Loss 16.99 2.20

Rigel Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.69 3.46 4.59 2.20 1.44

FRA:RI2 vs CADL, IMMX, AURA: PE Ratio (TTM) Comparison

For the Biotechnology subindustry, Rigel Pharmaceuticals's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rigel Pharmaceuticals PE Ratio (TTM) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Rigel Pharmaceuticals's PE Ratio (TTM) falls into.


FRA:RI2
76GF Score
Rigel Pharmaceuticals Inc FRA:RI2
PE Ratio (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rigel Pharmaceuticals PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Rigel Pharmaceuticals's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=33.80/16.032
=2.11

Rigel Pharmaceuticals's Share Price of today is €33.80.
Rigel Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €16.03.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio (TTM) →
What does a PE Ratio (TTM) of 2.11 mean?
Rigel Pharmaceuticals (FRA:RI2) has a PE Ratio (TTM) of 2.11 as of Jul. 03, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Rigel Pharmaceuticals and its competitors. This is 71% below median its historical median of 7.16. Over the past decade, Rigel Pharmaceuticals' PE Ratio (TTM) has ranged from 1.36 to 125.50. According to the industry distribution chart, Rigel Pharmaceuticals ranks #18 out of 272 companies in the Biotechnology industry, placing it in the top 6.6%.
Is Rigel Pharmaceuticals' PE Ratio (TTM) too high?
Rigel Pharmaceuticals' current PE Ratio (TTM) of 2.11 is 71% below median its 10-year median of 7.16. Over the past 10 years, this metric has ranged from a low of 1.36 to a high of 125.50. The Biotechnology industry median PE Ratio (TTM) is 27.48. Rigel Pharmaceuticals' value of 2.11 is 92.3% below this industry median. Based on the distribution chart, Rigel Pharmaceuticals ranks #18 out of 272 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Rigel Pharmaceuticals has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Rigel Pharmaceuticals' PE Ratio (TTM) compare to CADL and IMMX?
According to the Biotechnology industry distribution chart, Rigel Pharmaceuticals ranks #18 out of 272 companies for PE Ratio (TTM). This places Rigel Pharmaceuticals in the top 7% of its industry — outperforming the majority of peers. The industry median PE Ratio (TTM) is 27.48. Rigel Pharmaceuticals' value of 2.11 is 92.3% below this benchmark. Historically, Rigel Pharmaceuticals' own PE Ratio (TTM) has ranged from 1.36 to 125.50 over the past decade. While the company's 10-year median is 7.16 vs. the industry median of 27.48, Rigel Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Biotechnology company?
The median PE Ratio (TTM) among Biotechnology companies is 27.48, based on 272 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rigel Pharmaceuticals's current PE Ratio (TTM) of 2.11 is 92.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Rigel Pharmaceuticals and its competitors. For the Biotechnology industry, the median PE Ratio (TTM) is 27.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rigel Pharmaceuticals's current PE Ratio (TTM) is 2.11, which is 71% below median its own 10-year median of 7.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rigel Pharmaceuticals stock overvalued right now?
Rigel Pharmaceuticals (FRA:RI2) has a current PE Ratio (TTM) of 2.11. The stock's GF Value™ is €24.48, compared to a current price of €33.80 — trading 38.1% above its estimated fair value. The current PE Ratio (TTM) is 2.11, which is 71% below median its 10-year median of 7.16 and 92.3% below the Biotechnology industry median of 27.48. Rigel Pharmaceuticals' overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Rigel Pharmaceuticals (FRA:RI2), the current PE Ratio (TTM) is 2.11 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rigel Pharmaceuticals (FRA:RI2) Overvalued in 2026?

Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued. The current stock price of €33.80 is trading 38.1% above its estimated GF Value™ of €24.48.

Key valuation signals for FRA:RI2:

  • PE Ratio (TTM): 2.11 (71% below median its 10-year median of 7.16)
  • GF Value™: €24.48 vs. price of €33.80 (38.1% above fair value)
  • GF Score™: 76/100 with 7 warning signs
  • Industry Position: 92.3% below the Biotechnology median (#18 of 272)

No single metric tells the full story. See the FRA:RI2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Rigel Pharmaceuticals Business Description

Other Exchanges RIGL:USA
Address 611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
76GF Score

Get the complete analysis for FRA:RI2

PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€33.80
Price
€24.48
GF Value